Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

TREM2 Promotes Microglial Survival by Activating Wnt/β-Catenin Pathway.

The Journal of neuroscience : the official journal of the Society for Neuroscience | 2017

Triggering Receptor Expressed on Myeloid cells 2 (TREM2), which is expressed on myeloid cells including microglia in the CNS, has recently been identified as a risk factor for Alzheimer's disease (AD). TREM2 transmits intracellular signals through its transmembrane binding partner DNAX-activating protein 12 (DAP12). Homozygous mutations inactivating TREM2 or DAP12 lead to Nasu-Hakola disease; however, how AD risk-conferring variants increase AD risk is not clear. To elucidate the signaling pathways underlying reduced TREM2 expression or loss of function in microglia, we respectively knocked down and knocked out the expression of TREM2 in in vitro and in vivo models. We found that TREM2 deficiency reduced the viability and proliferation of primary microglia, reduced microgliosis in Trem2-/- mouse brains, induced cell cycle arrest at the G1/S checkpoint, and decreased the stability of β-catenin, a key component of the canonical Wnt signaling pathway responsible for maintaining many biological processes, including cell survival. TREM2 stabilized β-catenin by inhibiting its degradation via the Akt/GSK3β signaling pathway. More importantly, treatment with Wnt3a, LiCl, or TDZD-8, which activates the β-catenin-mediated Wnt signaling pathway, rescued microglia survival and microgliosis in Trem2-/- microglia and/or in Trem2-/- mouse brain. Together, our studies demonstrate a critical role of TREM2-mediated Wnt/β-catenin pathway in microglial viability and suggest that modulating this pathway therapeutically may help to combat the impaired microglial survival and microgliosis associated with AD.SIGNIFICANCE STATEMENT Mutations in the TREM2 (Triggering Receptor Expressed on Myeloid cells 2) gene are associated with increased risk for Alzheimer's disease (AD) with effective sizes comparable to that of the apolipoprotein E (APOE) ε4 allele, making it imperative to understand the molecular pathway(s) underlying TREM2 function in microglia. Our findings shed new light on the relationship between TREM2/DNAX-activating protein 12 (DAP12) signaling and Wnt/β-catenin signaling and provide clues as to how reduced TREM2 function might impair microglial survival in AD pathogenesis. We demonstrate that TREM2 promotes microglial survival by activating the Wnt/β-catenin signaling pathway and that it is possible to restore Wnt/β-catenin signaling when TREM2 activity is disrupted or reduced. Therefore, we demonstrate the potential for manipulating the TREM2/β-catenin signaling pathway for the treatment of AD.

Pubmed ID: 28077724 RIS Download

Associated grants

  • Agency: NINDS NIH HHS, United States
    Id: P01 NS074969
  • Agency: NIA NIH HHS, United States
    Id: R01 AG027924
  • Agency: NIA NIH HHS, United States
    Id: R01 AG046205
  • Agency: NIA NIH HHS, United States
    Id: P50 AG016574
  • Agency: NIA NIH HHS, United States
    Id: R01 AG035355
  • Agency: NIA NIH HHS, United States
    Id: RF1 AG056130
  • Agency: NIA NIH HHS, United States
    Id: RF1 AG046205

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


International Mouse Phenotyping Consortium (IMPC) (tool)

RRID:SCR_006158

Center that produces knockout mice and carries out high-throughput phenotyping of each line in order to determine function of every gene in mouse genome. These mice will be preserved in repositories and made available to scientific community representing valuable resource for basic scientific research as well as generating new models for human diseases.

View all literature mentions

Phospho-GSK-3 (Ser9) Antibody (antibody)

RRID:AB_331405

This polyclonal targets Phospho-GSK-3 (Ser9)

View all literature mentions

Cleaved Caspase-3 (Asp175) Antibody (antibody)

RRID:AB_2341188

This polyclonal targets Cleaved Caspase-3 (Asp175)

View all literature mentions

p44/42 MAPK (Erk1/2) Antibody (antibody)

RRID:AB_330744

This polyclonal targets p44/42 MAPK (Erk1/2)

View all literature mentions

Phospho-p38 MAPK (Thr180/Tyr182) Antibody (antibody)

RRID:AB_331641

This polyclonal targets p38 MAPK, phospho (Thr180 / Tyr182)

View all literature mentions

Akt (pan) (C67E7) Rabbit mAb (antibody)

RRID:AB_915783

This monoclonal targets Akt (pan) (C67E7) Rabbit mAb

View all literature mentions

Phospho-Akt (Ser473) Antibody (antibody)

RRID:AB_329825

This polyclonal targets Phospho-Akt (Ser473)

View all literature mentions

Bcl-2 (D17C4) Rabbit mAb (Mouse Preferred) (antibody)

RRID:AB_1903907

This monoclonal targets Bcl-2 (D17C4) Rabbit mAb (Mouse Preferred)

View all literature mentions

Cyclin D1 (92G2) Rabbit mAb (antibody)

RRID:AB_2259616

This monoclonal targets Cyclin D1

View all literature mentions